Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2, 2012. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,445 pence per share; lowest price paid was 1,422.5 pence per share.
- Treasury Holdings (Settled): 518,242,927 shares (9.31% of total issued share capital).
- Treasury Holdings (Including Unsettled): 520,997,927 shares (10.33% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,045,616,921 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,500,000 shares on May 2, 2012. This transaction increased the proportion of shares held in Treasury to 10.33% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (518,242,927 settled) against the company's latest 20-F annual report.
- Confirm the total issued share capital to validate the 9.31% treasury holding percentage.
- Check the settlement status of the 1,500,000 shares purchased on May 2, 2012, to reconcile the difference between settled and total treasury holdings.
- Review the Financial Services Authority's Disclosure and Transparency Rules to understand notification thresholds based on the 5,045,616,921 shares in issue.